BioSpace News Archive

The rise in the number of emergency cases such as heart attack and trauma-related attacks is estimated to be a significant factor for the growth of the intraosseous devices market during the forecast period of 2018-2026.

The drive for molecular biology enzymes, kits and reagents, stems from steady strides being made in life sciences industry.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, announced that a patient has passed away in the AAVance clinical trial, a global Phase 2/3 gene therapy trial for the treatment of Mucopolysaccharidosis Type IIIA.

United Therapeutics Corporation announced it will present clinical trial data on Tyvaso® Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease at CHEST 2020, the annual meeting of the American College of Chest Physicians, which will be held on October 18-21.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced its business highlights for the third quarter ended September 30, 2020.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that it will host a key opinion leader discussion on the unmet need in psoriasis and atopic dermatitis, including the potential of EDP1815 to serve as a new therapeutic option for patients living with mild to moderate disease.

Ina Phase 1/2interventional study, preliminary open-label safety resultsin first six patientssupport advancementof APL-9, an investigational targeted C3 therapy, for severe COVID-19; additional 60-patient randomized, double-blind, controlled study cohort is currently enrolling

Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned by Precision.

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to support development of SZN-043, a novel liver-targeted regenerative antibody.

Bio-Techne Corporation, a leading provider of proteins, antibodies and cytokines announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems.